top of page

RAD-140 (Testalone)
15mg/ml x 30ml INFORMATION

Description

RAD 140, also known as Testolone, is one of several selective androgen receptor modulators (SARMs) that was initially developed as a potential alternative to testosterone replacement therapy. It should not be confused with it’s esterified form, RAD 150, also known as TLB 150. Like all SARMs, RAD140 binds to the androgen receptors (AR) in a selective manner and does not produce the full range of androgenic effects as similar substances like testosterone, DHT, or anabolic steroids. RAD140 demonstrated excellent affinity for the AR (Ki = 7 nM), higher even than DHT and most anabolic steroids [1]. For reference, the the affinity for the androgen receptor (AR) for Testosterone in this preclinical model was 29 nM, and 10 nM for DHT. Unlike testosterone and most other AR mediated anabolic agents, Testolone is orally bioavailable so it does not require injection for proper absorption and it is considered by many researchers to be one of the best SARMs for bulking and adding lean body mass.

Testolone is a fairly recent addition to the list of SARMs for sale; it was developed in 2010 as a possible treatment for osteoporosis and muscle gains. More recent testing performed on rats and primates as well as a human clinical trial have indicated that it may provide additional benefits as well.

 

RAD 140 Mechanism of Action

In Vitro, the RAD140 SARM has produced a wide array of effects including:

  • Increased weight loss and body fat loss

  • Increased lean muscle growth and protein synthesis

  • Increased removal of beta amyloid plaques from the brain [2]

  • Increased protection against breast and prostate cancer

  • Increased endurance

 

Studies including RAD 140

However, it must be understood that the Food and Drug Administration (FDA) has not confirmed any health effects of RAD 140 for human beings or approved it for human use, and the drug should be used for laboratory research use only. Anecdotal reports indicate a potential for testosterone suppression and other side effects in males from RAD 140 administration. There have been a number of studies performed on animals, such as:

  • One study on rats found that RAD140 had neuroprotective benefits of a kind that may prevent Alzheimer’s disease and similar disorders, and may be safer than conventional testosterone therapy [3]. The group treated with 3 mg/kg RAD140 was able to replicate the same level of muscle tissue growth as the group treated with 1 mg/kg Testosterone, with about half of the androgenic activity in the prostate. [3].

  • RAD-140 has shown neuroprotective effects in another rat study by activating androgen receptors in the brain, protecting hippocampal neurons from cell death and reducing beta-amyloid plaque formation [2].

  • Another study, performed this time on primates, indicated that RAD140 may promote increases in lean muscle mass and muscle gains [1].

  • Androgen therapy has widely been considered in the fight against breast cancer but due to the side effects of anabolic steroids, SARMs like RAD-140 are being considered at this time. In a preclinical study RAD140 significantly suppressed the growth and proliferation of cancer cells in in vivo and in vitro models of AR/ER+ breast cancer [4].

 

Side effects of RAD 140

While RAD140 and other SARMs do not cause androgenic side effects to the same extent as anabolic steroids like Testosterone, anecdotal reports have revealed the potential for nausea, aggression, or mild male pattern hair loss from the use of RAD 140. A single-member case report indicated drug-induced liver injury after 11 months of the use of an anti-depressant, as well as intermittent use of RAD 140 and LGD-4033. The limitations of this study however are the fact that it includes only one test subject, 11 months of concurrent antidepressant use, the quality and dosage of SARMs used by the subject were not monitored, and that additional comorbidities were not investigated [7]. Several case reports exist indicating the potential for selective androgen receptor modulators to contribute to liver injury but none involve a significant sample size or test controls to date. Like other SARMs, RAD 140 may trigger a negative feedback loop and a reduction in natural testosterone production and testicle size though further research is needed to determine the likelihood and severity of this occurrence. 

 

RAD140 FAQs

Does RAD 140 suppress natural testosterone?

  • A study performed in 2010 found that After 28 days of dosing with RAD140, the testosterone levels in all three groups was suppressed to approximately 200−300 ng/dL, with similar suppression in all groups, although testosterone levels were significantly different for only the 0.01 mg/kg group (p < 0.05) [6].

Is RAD 140 safe for women?

  • Although it is not known to be particularly androgenic, there is little available information regarding the safety profile of RAD 140 in women and women should be cautious with participating in clinical research with RAD 140 until more information is available.


 

Can RAD 140 cause hair loss?

  • While it is not known to be particularly androgenic on its own, RAD 140 administration can free testosterone that is otherwise bound to SHBG in the male body and this can indirectly increase the risk of hair loss.

 

Abuse Warning

RAD 140 is an investigational compound still awaiting FDA approval and is not a dietary supplement. At Sports Technology Labs we are not medical doctors, and our expertise is sourcing and quality control. Sports Technology Labs does not encourage or condone consumer use of SARMs products, they are for research purposes only. Anecdotal reports online indicate RAD 140 dosage of 10mg and 20mg per day used by many individuals. A RAD 140 dose of 30mg per day has even been reported by several individuals in online forums. These dosages may not match those used in carefully designed medical research protocols and may pose a serious risk of adverse effects in users.

We consider the duplication of anecdotal protocols online to be a risky practice. SARMs should only be used under the supervision and direction of a medical doctor or designated research authority. We strongly discourage the use of SARMs for performance enhancement in sports and bodybuilding, and warn against “bro science” and peer consensus when making decisions about human health.

 

 

References:

  1. Miller, C. P., Shomali, M., Lyttle, C. R., O’Dea, L. S., Herendeen, H., Gallacher, K., Paquin, D., Compton, D. R., Sahoo, B., Kerrigan, S. A., Burge, M. S., Nickels, M., Green, J. L., Katzenellenbogen, J. A., Tchesnokov, A., & Hattersley, G. (2010). Design, Synthesis, and Preclinical Characterization of the Selective AR Modulator (SARM) RAD140. ACS medicinal chemistry letters, 2(2), 124–129. GW 501516 https://pubs.acs.org/doi/10.1021/ml1002508

  2. Jayaraman, A., Christensen, A., Moser, V. A., Vest, R. S., Miller, C. P., Hattersley, G., & Pike, C. J. (2014). Selective AR modulator RAD140 is neuroprotective in cultured neurons and kinate-lesioned male rats. Endocrinology, 155(4), 1398–1406. https://doi.org/10.1210/en.2013-1725

  3. D. K. Hamson, S. R. Wainwright, J. R. Taylor, B. A. Jones, N. V. Watson, L. A. M. Galea, Androgens Increase Survival of Adult-Born Neurons in the Dentate Gyrus by an Androgen Receptor-Dependent Mechanism in Male Rats, Endocrinology, Volume 154, Issue 9, 1 September 2013, Pages 3294–3304, https://doi.org/10.1210/en.2013-1129

  4. Yu, Ziyang et al. “Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive BC Models with a Distinct Mechanism of Action.” MK 677 Clinical Cancer Research 23 (2017): 7608 – 7620.

  5. LoRusso P, Hamilton E, Ma C, Vidula N, Bagley RG, Troy S, Annett M, Yu Z, Conlan MG, Weise A. A First-in-Human Phase 1 Study of a Novel Selective AR Modulator (SARM), RAD140, in ER+/HER2- Metastatic BC. Clin Br Cancer. 2022 Jan;22(1):67-77. doi: 10.1016/j.clbc.2021.08.003. Epub 2021 Aug 20. PMID: 34565686.

  6. Miller, C. P., Shomali, M., Lyttle, C. R., O’Dea, L. S., Herendeen, H., Gallacher, K., Paquin, D., Compton, D. R., Sahoo, B., Kerrigan, S. A., Burge, M. S., Nickels, M., Green, J. L., Katzenellenbogen, J. A., Tchesnokov, A., & Hattersley, G. (2010). Design, Synthesis, and Preclinical Characterization of the Selective AR Modulator (SARM) RAD140. ACS medicinal chemistry letters, 2(2), 124–129 https://doi.org/10.1021/ml1002508

  7. Flores JE, Chitturi S, Walker S. Drug-Induced Liver Injury by Selective Androgenic Receptor Modulators. Hepatol Commun. 2020 Jan 3;4(3):450-452. doi: 10.1002/hep4.1456. PMID: 32140660; PMCID: PMC7049679.

bottom of page